Ignite Creation Date:
2026-03-26 @ 3:20 PM
Ignite Modification Date:
2026-03-31 @ 2:53 PM
Study NCT ID:
NCT07422805
Status:
COMPLETED
Last Update Posted:
2026-02-24
First Post:
2026-02-05
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Circulating Tumor DNA in Melanoma Patients
Sponsor:
Institute of Oncology Ljubljana
Organization:
Study Overview
Official Title:
Significance of Detection and Quantification of Circulating Tumor DNA in the Treatment of Melanoma Patients
Status:
COMPLETED
Status Verified Date:
2026-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ctDNA
Brief Summary:
The aim of this prospective observational study is to determine whether the presence and quantity of circulating tumor DNA (ctDNA) can serve as a predictive factor for recurrence or progression of melanoma. The study will evaluate the association between ctDNA detection and quantification and relevant clinical and histopathological prognostic parameters. The goal is to assess whether ctDNA may be useful as a biomarker for monitoring disease course and predicting outcomes in melanoma patients.
Detailed Description:
This is a prospective observational cohort study designed to evaluate the clinical significance of circulating tumor DNA (ctDNA) detection and quantification in patients with melanoma. The main purpose of the study is to determine whether the presence and quantity of ctDNA may represent a predictive biomarker for melanoma recurrence or disease progression.
The study will assess the relationship between ctDNA levels and established clinical and histopathological prognostic factors. ctDNA detection and quantification will be performed and correlated with relevant patient and tumor characteristics. The study will also evaluate whether ctDNA measurement can contribute to improved monitoring of melanoma patients and prediction of treatment outcomes.
The study is conducted at the Institute of Oncology Ljubljana as a prospective cohort study and includes melanoma patients who are followed over time. The collected data will be analyzed to determine associations between ctDNA presence/quantity and recurrence or progression of melanoma.
The study will assess the relationship between ctDNA levels and established clinical and histopathological prognostic factors. ctDNA detection and quantification will be performed and correlated with relevant patient and tumor characteristics. The study will also evaluate whether ctDNA measurement can contribute to improved monitoring of melanoma patients and prediction of treatment outcomes.
The study is conducted at the Institute of Oncology Ljubljana as a prospective cohort study and includes melanoma patients who are followed over time. The collected data will be analyzed to determine associations between ctDNA presence/quantity and recurrence or progression of melanoma.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| ERIDEK-0084/2021 | OTHER | Institute of Oncology Ljubljana (ali Ethics Committee of the Institute of Oncology Ljubljana) | View |